Genomics

Dataset Information

0

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity [ChIP-Seq, ATAC-Seq]


ABSTRACT: Targeting chromatin binding proteins and modifying enzymes can concomitantly affect tumor cell proliferation and survival, as well as enhance anti-tumor immunity and augment cancer immunotherapies. By screening a small molecule library of epigenetics-based therapeutics, BET bromodomain inhibitors (BETi) were identified as agents that sensitize tumor cells to the anti-tumor activity of CD8+ T-cells. BETi modulated tumor cells to be sensitized to the cytotoxic effects of the pro-inflammatory cytokine TNF. By preventing the recruitment of BRD4 to p65-bound cis-regulatory elements, BETi suppressed the induction of inflammatory gene expression, including the key NF-B target genes BIRC2 (cIAP1) and BIRC3 (cIAP2). Disruption of pro-survival NF-B signaling by BETi led to unrestrained TNF-mediated activation of the extrinsic apoptotic cascade and tumor cell death. Administration of BETi in combination with T-cell bispecific (TCB) antibodies increased bystander killing of tumor cells and enhanced tumor growth inhibition in vivo in a TNF-dependent manner. This novel epigenetic mechanism of immunomodulation may guide future use of BETi as adjuvants for immune oncology agents.

ORGANISM(S): Mus musculus

PROVIDER: GSE184591 | GEO | 2021/09/24

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-09-24 | GSE184589 | GEO
2016-09-01 | E-GEOD-73639 | biostudies-arrayexpress
2023-01-25 | GSE222095 | GEO
2016-09-01 | E-GEOD-73281 | biostudies-arrayexpress
2016-09-01 | GSE73639 | GEO
2016-09-01 | GSE73281 | GEO
2024-05-24 | PXD042585 | Pride
2007-10-29 | GSE8477 | GEO
2007-10-29 | GSE8476 | GEO
2024-03-13 | GSE261177 | GEO